• Oral formulations of 5-aminosalicylic acid: first-line medications to induce and maintain remission
• Conventional corticosteroids: given to patients who do not respond to 5-ASA formulations within 10 to 14 days
• Azathioprine and 6-mercaptopurine: American Gastroenterological Association and American College of Gastroenterology guidelines suggest AZA or 6-mercaptopurine for patients with severe flares of UC
• Cyclosporine: intravenous cyclosporine A is a second-line therapy for patients with severe and corticosteroid-refractory UC
• Anit-TNF antibodies: infliximab, adalimumab and golimumab
More Articles on Gastroenterology:
6 Things to Know About Ulcerative Colitis, Crohn’s Disease & Cancer Risk
3 Things to Know About Celiac Disease Screening
Dr. Michael Uzer Joins Sarah Bush Lincoln Health Center
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
